Rx0000101 |
Par Pharmaceutical |
09/30/2022 |
42023010501 |
BREVITAL SODIUM METHOHEXITAL SODIUM INJECTABLE 500MG/VIAL |
09/19/2022 |
15.01 |
85.92 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 10/20/2022, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the patent expiration date field for this product blank.(3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns 14-22 blank because they are not applicable to this product. |
Rx0000101 |
Par Pharmaceutical |
09/30/2022 |
42023011925 |
TIGAN TRIMETHOBENZAMIDE HYDROCHLORIDE INJECTABLE 100MG/ML, 25vl |
09/19/2022 |
203.95 |
1167.61 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 10/20/2022, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the patent expiration date field for this product blank.(3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns 14-22 blank because they are not applicable to this product. |
Rx0000053 |
Paratek Pharmaceuticals, Inc. |
03/31/2022 |
71715000227 |
Nuzyra Oral Tablet 150 MG 30 pack |
01/01/2022 |
204.30 |
7014.41 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000053 |
Paratek Pharmaceuticals, Inc. |
09/30/2022 |
71715000227 |
Nuzyra Oral Tablet 150 MG 30 pack |
07/01/2022 |
210.43 |
7224.84 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000053 |
Paratek Pharmaceuticals, Inc. |
03/31/2022 |
71715000221 |
Nuzyra Oral Tablet 150 MG 6 pack |
01/01/2022 |
40.86 |
1402.88 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000053 |
Paratek Pharmaceuticals, Inc. |
09/30/2022 |
71715000221 |
Nuzyra Oral Tablet 150 MG 6 pack |
07/01/2022 |
42.09 |
1444.95 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000006 |
Pfizer |
03/31/2022 |
00409592101 |
AMINOPHYLLINE (aminophylline), 250 mg/10 mL, VIAL (ML), 1 |
01/01/2022 |
31.25 |
343.77 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00409592201 |
AMINOPHYLLINE (aminophylline), 500 mg/20 mL, VIAL (ML), 1 |
01/01/2022 |
20.11 |
221.25 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00009722402 |
ATGAM (lymphocyte immune globulin,antithymocyte (equine)), 50 mg/mL, Ampul(ML), 5 |
01/01/2022 |
2862.89 |
14314.46 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00409963005 |
ATROPINE SULFATE (atropine sulfate), 0.05 mg/mL, SYRINGE (ML), 1 |
01/01/2022 |
13.92 |
153.08 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00409491134 |
ATROPINE SULFATE (atropine sulfate), 0.1 mg/mL, SYRINGE (ML), 1 |
01/01/2022 |
10.42 |
114.62 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00409491034 |
ATROPINE SULFATE (atropine sulfate), 0.1 mg/mL, SYRINGE (ML), 1 |
01/01/2022 |
9.10 |
100.05 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00409163010 |
ATROPINE SULFATE (atropine sulfate), 0.1 mg/mL, SYRINGE (ML), 1 |
01/01/2022 |
5.80 |
63.75 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00409963005 |
Atropine Sulfate Injection Rx, 0.05 mg/mL (0.25 mg/5 mL) Ansyr™ Plastic Syringe, 10 |
07/01/2022 |
15.31 |
168.39 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00409491034 |
Atropine Sulfate Injection Rx, 0.1 mg/mL (0.5 mg/5 mL) LifeShield™ Abboject™ Glass Syringe (20 G x 1 1/2"), 10 |
07/01/2022 |
10.01 |
110.06 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00409163010 |
Atropine Sulfate Injection Rx, 0.1 mg/mL (1 mg/10 mL) Ansyr™ Plastic Syringe, 10 |
07/01/2022 |
6.38 |
70.13 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00409491134 |
Atropine Sulfate Injection Rx, 0.1 mg/mL (1 mg/10 mL) LifeShield™ Abboject™ Glass Syringe (20 G x 1 1/2"), 10 |
07/01/2022 |
11.46 |
126.08 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00409196612 |
Bacteriostatic 0.9% Sodium Chloride Injection Rx, 10 mL (0.9%) Multiple Dose LifeShield™ Plastic Fliptop Vial, 25 |
07/01/2022 |
4.38 |
48.18 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00409397703 |
Bacteriostatic Water Injection Rx, 30 mL Multiple Dose Plastic Fliptop Vial, 25 |
07/01/2022 |
3.73 |
41.00 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
60793060110 |
BICILLIN C-R (penicillin G benzathine/penicillin G procaine), 1,200,000 unit/2 mL (600,000/600,000), SYRINGE (ML), 1 |
01/01/2022 |
137.23 |
1509.57 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
60793060010 |
BICILLIN C-R (penicillin G benzathine/penicillin G procaine), 1,200,000 unit/2 mL (600,000/600,000), SYRINGE (ML), 1 |
01/01/2022 |
137.23 |
1509.57 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
60793060210 |
BICILLIN C-R (penicillin G benzathine/penicillin G procaine), 1,200,000 unit/2 mL (900,000/300,000), SYRINGE (ML), 1 |
01/01/2022 |
137.23 |
1509.57 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
60793060210 |
Bicillin C-R 900/300® (penicillin G benzathine and penicillin G procaine suspension) Injection Rx, 2 mL Pre-filled Syringe (21 gauge x 1" needle) Pediatric, 10 |
07/01/2022 |
150.96 |
1660.53 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
60793060110 |
Bicillin C-R® (penicillin G benzathine and penicillin G procaine suspension) Injection Rx, 2 mL Pre-filled Syringe (21 gauge x 1" needle) Pediatric, 10 |
07/01/2022 |
150.96 |
1660.53 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
60793060010 |
Bicillin C-R® (penicillin G benzathine and penicillin G procaine suspension) Injection Rx, 2 mL Pre-filled Syringe (21 gauge x 1-1/2" needle), 10 |
07/01/2022 |
150.96 |
1660.53 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
60793070110 |
BICILLIN L-A (penicillin G benzathine), 1.2 million unit/2 mL, SYRINGE (ML), 1 |
01/01/2022 |
172.16 |
1893.74 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
60793070210 |
BICILLIN L-A (penicillin G benzathine), 2.4 million unit/4 mL, SYRINGE (ML), 1 |
01/01/2022 |
352.78 |
3880.58 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
60793070010 |
BICILLIN L-A (penicillin G benzathine), 600,000 unit/mL, SYRINGE (ML), 1 |
01/01/2022 |
99.40 |
1093.41 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
60793070010 |
Bicillin L-A® (penicillin G benzathine suspension) Injection Rx, 1 mL Pre-Filled Syringe (21 gauge x 1" needle) Pediatric, 10 |
07/01/2022 |
109.34 |
1202.75 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
60793070110 |
Bicillin L-A® (penicillin G benzathine suspension) Injection Rx, 2 mL Pre-Filled Syringe (21 gauge x 1-1/2" needle), 10 |
07/01/2022 |
189.37 |
2083.11 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
60793070210 |
Bicillin L-A® (penicillin G benzathine suspension) Injection Rx, 4 mL Pre-Filled Syringe (18 gauge x 1-1/2" needle), 10 |
07/01/2022 |
388.06 |
4268.64 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00069013501 |
BOSULIF (bosutinib), 100 mg, TABLET, 1 |
01/01/2022 |
905.11 |
17361.70 |
04/01/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00069019301 |
BOSULIF (bosutinib), 400 mg, TABLET, 1 |
01/01/2022 |
905.11 |
17361.70 |
04/01/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00069013601 |
BOSULIF (bosutinib), 500 mg, TABLET, 1 |
01/01/2022 |
905.11 |
17361.70 |
04/01/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00409162301 |
Butorphanol Tartrate Injection - Controlled Substance - SCHEDULE IV Rx, 1 mg/mL (1 mg/mL) Single Dose Glass Fliptop Vial, 10 |
07/01/2022 |
4.61 |
50.67 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00409162601 |
Butorphanol Tartrate Injection - Controlled Substance - SCHEDULE IV Rx, 2 mg/mL (2 mg/mL) Single Dose Glass Fliptop Vial, 10 |
07/01/2022 |
5.63 |
61.97 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00409162602 |
Butorphanol Tartrate Injection - Controlled Substance - SCHEDULE IV Rx, 2 mg/mL (4 mg/2 mL) Single Dose Glass Fliptop Vial, 10 |
07/01/2022 |
7.93 |
87.25 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00409492834 |
CALCIUM CHLORIDE (calcium chloride), 100 mg/mL (10 %), SYRINGE (ML), 1 |
01/01/2022 |
9.65 |
106.15 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00409163110 |
Calcium Chloride Injection Rx, 100 mg/mL (1 g/10 mL) Ansyr™ Plastic Syringe, 10 |
07/01/2022 |
7.84 |
86.20 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00409492834 |
Calcium Chloride Injection Rx, 100 mg/mL (1 g/10 mL) LifeShield™ Abboject™ Glass Syringe (20 G x 1 1/2"), 10 |
07/01/2022 |
10.62 |
116.77 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00409337301 |
Corlopam® (fenoldopam mesylate) Injection Rx, 10 mg Single Dose Vial, 1 |
07/01/2022 |
41.36 |
454.95 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00409337302 |
Corlopam® (fenoldopam mesylate) Injection Rx, 20 mg Single Dose Vial, 1 |
07/01/2022 |
82.72 |
909.91 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00069153130 |
DAURISMO (glasdegib maleate), 100 mg, TABLET, 1 |
01/01/2022 |
1026.29 |
19686.10 |
01/30/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
(4) The patent expiration date listed is based on a pending patent term extension application and the patent expiry date is expected to be 2031 upon the grant of the patent term extension application. |
Rx0000006 |
Pfizer |
03/31/2022 |
00069029860 |
DAURISMO (glasdegib maleate), 25 mg, TABLET, 1 |
01/01/2022 |
1026.29 |
19686.10 |
01/30/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
(4) The patent expiration date listed is based on a pending patent term extension application and the patent expiry date is expected to be 2031 upon the grant of the patent term extension application. |
Rx0000006 |
Pfizer |
03/31/2022 |
00409125502 |
DEMEROL (meperidine HCl/PF), 100 mg/2 mL, AMPUL (ML), 1 |
01/01/2022 |
5.51 |
115.78 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00409118130 |
Demerol™ (meperidine hydrochloride) Injection - Controlled Substance - SCHEDULE II Rx, 50 mg/mL (1,500 mg/30 mL) Multiple Dose Glass Fliptop Vial, 1 |
07/01/2022 |
4.06 |
85.32 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00009027101 |
DEPO-ESTRADIOL (estradiol cypionate), 5 mg/mL, VIAL (ML), 1 |
01/01/2022 |
11.58 |
127.35 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00009027101 |
Depo-Estradiol® (estradiol cypionate) Sterile Solution Rx, 5 mg/mL 5 mL Vial, 1 |
07/01/2022 |
12.74 |
140.09 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00409177510 |
DEXTROSE IN WATER (dextrose 25 % in water), 25 %, SYRINGE (ML), 1 |
01/01/2022 |
9.60 |
105.64 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00409490234 |
DEXTROSE IN WATER (dextrose 50 % in water), 50 %, SYRINGE (ML), 1 |
01/01/2022 |
9.41 |
103.49 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00409751716 |
DEXTROSE IN WATER (dextrose 50 % in water), 50 %, SYRINGE (ML), 1 |
01/01/2022 |
9.20 |
101.22 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00409664802 |
DEXTROSE IN WATER (dextrose 50 % in water), 50 %, VIAL (ML), 1 |
01/01/2022 |
7.76 |
85.39 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00409751716 |
Dextrose Injection Rx, 0.5 g/mL (25 g/50 mL) (50%) Ansyr™ II Plastic Syringe (side/side), 10 |
07/01/2022 |
10.12 |
111.34 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00409490234 |
Dextrose Injection Rx, 0.5 g/mL (25 g/50 mL) (50%) LifeShield™ Abboject™ Glass Syringe (18 G x 1 1/2"), 10 |
07/01/2022 |
10.35 |
113.84 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00409664802 |
Dextrose Injection Rx, 0.5 g/mL (25 g/50 mL) (50%) Single Dose Glass Fliptop Vial, 25 |
07/01/2022 |
8.54 |
93.93 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00409710067 |
Dextrose Injection Rx, 100 mL (5%) ADD-Vantage™ Flexible Container, 50 |
07/01/2022 |
13.63 |
149.92 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00409177510 |
Dextrose Injection Rx, 250 mg/mL (2.5 g/10 mL) (25%) Ansyr™ Plastic Syringe, 10 |
07/01/2022 |
10.56 |
116.20 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00409710002 |
Dextrose Injection Rx, 250 mL (5%) ADD-Vantage™ Flexible Container, 24 |
07/01/2022 |
8.68 |
95.45 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00409710066 |
Dextrose Injection Rx, 50 mL (5%) ADD-Vantage™ Flexible Container, 50 |
07/01/2022 |
13.46 |
148.02 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00409910420 |
DOPAMINE HCL (dopamine HCl), 400 mg/10 mL (40 mg/mL), VIAL (ML), 1 |
01/01/2022 |
5.41 |
59.46 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00409493301 |
Epinephrine Injection Rx, 1mg/10mL (0.1 mg/mL) ABBOJECT Single-dose syringe, 10 |
07/01/2022 |
5.76 |
63.38 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00069021702 |
Fragmin® (dalteparin sodium) Injection Rx, 10,000 IU/1 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards, 10 |
07/01/2022 |
90.73 |
998.07 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00069022002 |
Fragmin® (dalteparin sodium) Injection Rx, 12,500 IU/0.5 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards, 10 |
07/01/2022 |
113.43 |
1247.68 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00069022302 |
Fragmin® (dalteparin sodium) Injection Rx, 15,000 IU/0.6 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards, 10 |
07/01/2022 |
136.10 |
1497.13 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00069022802 |
Fragmin® (dalteparin sodium) Injection Rx, 18,000 IU/0.72 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards test potency, 10 |
07/01/2022 |
163.32 |
1796.55 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00069019502 |
Fragmin® (dalteparin sodium) Injection Rx, 2,500 IU/0.2 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards, 10 |
07/01/2022 |
27.96 |
307.59 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00069019602 |
Fragmin® (dalteparin sodium) Injection Rx, 5,000 IU/0.2 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards, 10 |
07/01/2022 |
45.37 |
499.04 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00069020602 |
Fragmin® (dalteparin sodium) Injection Rx, 7,500 IU/0.3 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards, 10 |
07/01/2022 |
68.06 |
748.64 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00069023201 |
Fragmin® (dalteparin sodium) Injection Rx, 95,000 IU/3.8 mL Multidose Vial, 1 |
07/01/2022 |
77.99 |
857.89 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00409163910 |
FUROSEMIDE (furosemide), 10 mg/mL, SYRINGE (ML), 1 |
01/01/2022 |
18.54 |
203.94 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00409963104 |
FUROSEMIDE (furosemide), 10 mg/mL, SYRINGE (ML), 1 |
01/01/2022 |
11.12 |
122.34 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00409163910 |
Furosemide Injection Rx, 10 mg/mL (100 mg/10 mL) Ansyr™ Plastic Syringe, 10 |
07/01/2022 |
20.39 |
224.33 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00409963104 |
Furosemide Injection Rx, 10 mg/mL (40 mg/4 mL) Ansyr™ Plastic Syringe, 10 |
07/01/2022 |
12.23 |
134.57 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00409120703 |
Gentamicin Sulfate Injection Rx, 40 mg/mL (80 mg/2 mL) Single Dose Glass Fliptop Vial, 25 |
07/01/2022 |
7.04 |
35.21 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00409765062 |
Heparin Sodium (0.45% Sodium Chloride) Injection Rx, 100 Units/mL (25,000 Units/250 mL) Flexible Container, 24 |
07/01/2022 |
23.32 |
256.51 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00409765162 |
Heparin Sodium (0.45% Sodium Chloride) Injection Rx, 50 Units/mL (12,500 Units/250 mL) Flexible Container, 24 |
07/01/2022 |
20.17 |
221.87 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00069013703 |
HEPARIN SODIUM (heparin sodium,porcine), 1,000 unit/mL, VIAL (ML), 1 |
01/01/2022 |
0.77 |
77.74 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00069005801 |
HEPARIN SODIUM (heparin sodium,porcine), 1,000 unit/mL, VIAL (ML), 1 |
01/01/2022 |
0.84 |
84.35 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00409272003 |
HEPARIN SODIUM (heparin sodium,porcine), 1,000 unit/mL, VIAL (ML), 1 |
01/01/2022 |
1.92 |
194.31 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00409272001 |
HEPARIN SODIUM (heparin sodium,porcine), 1,000 unit/mL, VIAL (ML), 1 |
01/01/2022 |
0.46 |
46.40 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00409272002 |
HEPARIN SODIUM (heparin sodium,porcine), 1,000 unit/mL, VIAL (ML), 1 |
01/01/2022 |
0.84 |
84.35 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00409272101 |
HEPARIN SODIUM (heparin sodium,porcine), 10,000 unit/mL, VIAL (ML), 1 |
01/01/2022 |
0.81 |
82.30 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00409140212 |
HEPARIN SODIUM (heparin sodium,porcine), 5,000 unit/mL (1 mL), CARTRIDGE (ML), 1 |
01/01/2022 |
1.43 |
144.74 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00069005901 |
HEPARIN SODIUM (heparin sodium,porcine), 5,000 unit/mL, VIAL (ML), 1 |
01/01/2022 |
2.88 |
291.24 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00409272301 |
HEPARIN SODIUM (heparin sodium,porcine), 5,000 unit/mL, VIAL (ML), 1 |
01/01/2022 |
0.50 |
50.49 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00069005903 |
HEPARIN SODIUM (heparin sodium,porcine), 5,000 unit/mL, VIAL (ML), 1 |
01/01/2022 |
1.04 |
105.06 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00409272302 |
HEPARIN SODIUM (heparin sodium,porcine), 5,000 unit/mL, VIAL (ML),1 |
01/01/2022 |
2.88 |
291.24 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00409131632 |
HEPARIN SODIUM (heparin sodium,porcine/PF), 5,000 unit/0.5 mL, CARTRIDGE (ML), 1 |
01/01/2022 |
4.98 |
170.84 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00409765062 |
HEPARIN SODIUM IN 0.45% NACL (heparin sodium,porcine in 0.45 % sodium chloride), 25,000 unit/250 mL (100 unit/mL), INTRAVENOUS SOLUTION, 1 |
01/01/2022 |
1.16 |
233.19 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00409765162 |
HEPARIN SODIUM-0.45% NACL (heparin sodium,porcine in 0.45 % sodium chloride), 12,500 unit/250 mL, INTRAVENOUS SOLUTION, 1 |
01/01/2022 |
1.00 |
201.70 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00409765103 |
HEPARIN SODIUM-0.45% NACL (heparin sodium,porcine in 0.45 % sodium chloride), 25,000 unit/500 mL (50 unit/mL), INTRAVENOUS SOLUTION, 1 |
01/01/2022 |
17.58 |
193.33 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00409762003 |
HEPARIN SODIUM-0.9% NACL (heparin sodium,porcine IN 0.9 % sodium chloride/PF), 1,000 unit/500 mL (2 unit/mL), INTRAVENOUS SOLUTION, 1 |
01/01/2022 |
0.98 |
98.91 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00409762059 |
HEPARIN SODIUM-0.9% NACL (heparin sodium,porcine IN 0.9 % sodium chloride/PF), 2,000 unit/1,000 mL (2 unit/mL), INTRAVENOUS SOLUTION, 1 |
01/01/2022 |
0.80 |
80.78 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00409779362 |
HEPARIN SODIUM-D5W (heparin sodium,porcine/dextrose 5 % in water), 25,000 unit/250 mL (100 unit/mL), INTRAVENOUS SOLUTION, 1 |
01/01/2022 |
2.29 |
230.99 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00409128305 |
Hydromorphone Hydrochloride Injection - Controlled Substance - SCHEDULE II Rx, 1 mg/mL (0.5 mg/0.5 mL) iSecure™ Luer Lock Glass Syringe (no needle), 10 |
07/01/2022 |
2.85 |
31.35 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00409255201 |
Hydromorphone Hydrochloride Injection - Controlled Substance - SCHEDULE II Rx, 1 mg/mL (1 mg/1 mL) Glass Ampul, 10 |
07/01/2022 |
2.03 |
22.37 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00069018821 |
IBRANCE (palbociclib), 100 mg, CAPSULE, 1 |
01/01/2022 |
901.96 |
13973.80 |
03/05/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00069018921 |
IBRANCE (palbociclib), 125 mg, CAPSULE, 1 |
01/01/2022 |
901.96 |
13973.80 |
03/05/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00069018721 |
IBRANCE (palbociclib), 75 mg, CAPSULE, 1 |
01/01/2022 |
901.96 |
13973.80 |
03/05/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00069014501 |
INLYTA (axitinib), 1 mg, TABLET, 1 |
01/01/2022 |
1147.36 |
17775.76 |
04/29/2025 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00069015111 |
INLYTA (axitinib), 5 mg, TABLET, 1 |
01/01/2022 |
1147.36 |
17775.76 |
04/29/2025 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00409913705 |
LIDOCAINE HCL (lidocaine HCl/PF), 50 mg/5 mL (1 %), SYRINGE (ML), 1 |
01/01/2022 |
6.99 |
76.90 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00409490434 |
LIDOCAINE HCL (lidocaine HCl/PF), 50 mg/5 mL (1 %), SYRINGE (ML), 1 |
01/01/2022 |
10.16 |
111.72 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00409913705 |
Lidocaine Hydrochloride Injection Rx, 1% (10 mg/mL) 50 mg/5 mL Ansyr™ Plastic Syringe, 10 |
07/01/2022 |
7.69 |
84.59 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00409490434 |
Lidocaine Hydrochloride Injection Rx, 1% (10 mg/mL) 50 mg/5 mL LifeShield™ Abboject™ Glass Syringe (20 G x 1 1/2"), 10 |
07/01/2022 |
11.17 |
122.89 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00409132305 |
Lidocaine Hydrochloride Injection Rx, 2% (20 mg/mL) 100 mg/5 mL Ansyr™ Plastic Syringe, 10 |
07/01/2022 |
3.73 |
41.04 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00409490334 |
Lidocaine Hydrochloride Injection Rx, 2% (20 mg/mL) 100 mg/5 mL LifeShield™ Abboject™ Glass Syringe (20 G x 1 1/2"), 10 |
07/01/2022 |
3.89 |
42.82 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00069023101 |
LORBRENA (lorlatinib), 100 mg, TABLET, 1 |
01/01/2022 |
973.58 |
18675.11 |
03/05/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00069022701 |
LORBRENA (lorlatinib), 25 mg, TABLET, 1 |
01/01/2022 |
324.53 |
6225.05 |
03/05/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00409175410 |
MAGNESIUM SULFATE (magnesium sulfate), 4 mEq/mL (50 %), SYRINGE (ML), 1 |
01/01/2022 |
19.01 |
209.12 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00409175410 |
Magnesium Sulfate Injection Rx, 500 mg/mL (5 g/10 mL) Ansyr™ Plastic Syringe, 10 |
07/01/2022 |
20.91 |
230.03 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00409259603 |
MIDAZOLAM HCL (midazolam HCl), 5 mg/mL, VIAL (ML), 1 |
01/01/2022 |
0.44 |
44.44 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00409464601 |
PANCURONIUM BROMIDE (pancuronium bromide), 1 mg/mL, VIAL (ML), 1 |
01/01/2022 |
6.81 |
142.93 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
06/30/2022 |
00069101102 |
Panzyga (immune globulin intravenous, human - ifas) 1 g/10 mL Vial, 1 |
04/01/2022 |
2.84 |
193.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
06/30/2022 |
00069131202 |
Panzyga (immune globulin intravenous, human - ifas) 10 g/100 mL Vial, 1 |
04/01/2022 |
28.40 |
1930.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
06/30/2022 |
00069110902 |
Panzyga (immune globulin intravenous, human - ifas) 2.5 g/25 mL Vial, 1 |
04/01/2022 |
7.10 |
482.50 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
06/30/2022 |
00069141502 |
Panzyga (immune globulin intravenous, human - ifas) 20 g/200 mL Vial, 1 |
04/01/2022 |
56.80 |
3860.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
06/30/2022 |
00069155802 |
Panzyga (immune globulin intravenous, human - ifas) 30 g/300 mL Vial, 1 |
04/01/2022 |
85.20 |
5790.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
06/30/2022 |
00069122402 |
Panzyga (immune globulin intravenous, human - ifas) 5 g/50 mL Vial, 1 |
04/01/2022 |
14.20 |
965.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00069101102 |
Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 1 g/10 mL Vial, 1 |
07/01/2022 |
2.90 |
195.90 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
12/31/2022 |
00069101102 |
Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 1 g/10 mL Vial, 1 |
10/01/2022 |
2.94 |
198.84 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00069131202 |
Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 10 g/100 mL Vial, 1 |
07/01/2022 |
29.00 |
1959.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
12/31/2022 |
00069131202 |
Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 10 g/100 mL Vial, 1 |
10/01/2022 |
29.40 |
1988.40 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00069110902 |
Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 2.5 g/25 mL Vial, 1 |
07/01/2022 |
7.25 |
489.75 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
12/31/2022 |
00069110902 |
Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 2.5 g/25 mL Vial, 1 |
10/01/2022 |
7.35 |
497.10 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00069141502 |
Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 20 g/200 mL Vial, 1 |
07/01/2022 |
58.00 |
3918.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
12/31/2022 |
00069141502 |
Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 20 g/200 mL Vial, 1 |
10/01/2022 |
58.80 |
3976.80 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00069155802 |
Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 30 g/300 mL Vial, 1 |
07/01/2022 |
87.00 |
5877.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
12/31/2022 |
00069155802 |
Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 30 g/300 mL Vial, 1 |
10/01/2022 |
88.20 |
5965.20 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00069122402 |
Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 5 g/50 mL Vial, 1 |
07/01/2022 |
14.50 |
979.50 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
12/31/2022 |
00069122402 |
Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 5 g/50 mL Vial, 1 |
10/01/2022 |
14.70 |
994.20 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
60793013010 |
Penicillin G Procaine Injectable Suspension Rx, 1 mL Pre-filled Syringe (21 gauge x 1-1/2" needle), 1 |
07/01/2022 |
37.98 |
417.74 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
60793013110 |
Penicillin G Procaine Injectable Suspension Rx, 2 mL Pre-filled Syringe (21 gauge x 1-1/2" needle), 1 |
07/01/2022 |
63.84 |
702.25 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00005197105 |
PREVNAR 13 (pneumococcal 13-valent conjugate vaccine (Diphtheria crm) / PF), 0.5 mL, SYRINGE (ML), 1 |
01/01/2022 |
15.02 |
232.76 |
11/09/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00005197102 |
PREVNAR 13 (pneumococcal 13-valent conjugate vaccine (Diphtheria crm)/PF), 0.5 mL, SYRINGE (ML), 1 |
01/01/2022 |
145.67 |
2256.81 |
11/09/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00409553414 |
Sodium Bicarbonate Injection Rx, 4.2% (5mEq/10mL) per glass Abboject® syringe, 10 |
07/01/2022 |
12.49 |
137.35 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00409491614 |
Sodium Bicarbonate Injection Rx, 7.5% (44/6 mEq/50mL) per glass Abboject® syringe, 10 |
07/01/2022 |
16.17 |
177.90 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00409490014 |
Sodium Bicarbonate Injection Rx, 8.4% (10mEq/10mL) per glass vial Abboject® syringe, 10 |
07/01/2022 |
16.13 |
177.39 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00409663714 |
Sodium Bicarbonate Injection Rx, 8.4% (50mEq/50mL) per glass Abbotject® syringe, 10 |
07/01/2022 |
11.91 |
131.01 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00409488850 |
SODIUM CHLORIDE (0.9 % sodium chloride), 0.9 %, VIAL (ML), 1 |
01/01/2022 |
6.38 |
70.15 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00409488812 |
SODIUM CHLORIDE (0.9 % sodium chloride), 0.9 %, VIAL (ML), 1 |
01/01/2022 |
4.15 |
45.65 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00409196612 |
SODIUM CHLORIDE (bacteriostatic sodium chloride), 0.9 %, VIAL (ML), 1 |
01/01/2022 |
3.98 |
43.80 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00409114102 |
SODIUM CHLORIDE (sodium chloride), 4 mEq/mL, VIAL (ML), 1 |
01/01/2022 |
0.96 |
96.88 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00409488812 |
Sodium Chloride Injection Rx, 0.9% (10 mL) Single Dose LifeShield™ Plastic Fliptop Vial, 25 |
07/01/2022 |
4.57 |
50.22 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00409710167 |
Sodium Chloride Injection Rx, 0.9% (100 mL) ADD-Vantage™ Flexible Container, 50 |
07/01/2022 |
13.80 |
151.83 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00409710102 |
Sodium Chloride Injection Rx, 0.9% (250 mL) ADD-Vantage™ Flexible Container, 24 |
07/01/2022 |
8.73 |
96.05 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00409710166 |
Sodium Chloride Injection Rx, 0.9% (50 mL) ADD-Vantage™ Flexible Container, 50 |
07/01/2022 |
13.98 |
153.74 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
09/30/2022 |
00409488850 |
Sodium Chloride Injection Rx, 0.9% (50 mL) Single Dose Plastic Fliptop Vial, 25 |
07/01/2022 |
7.02 |
77.17 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00409666075 |
SODIUM CHLORIDE, 2.5 mEq/mL, Vial, 40 |
01/01/2022 |
4.93 |
39.86 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00009082501 |
SOLU-CORTEF (hydrocortisone sodium succinate), 100 mg, Vial, 1 |
01/01/2022 |
2.28 |
13.69 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00009000501 |
SOLU-CORTEF (hydrocortisone sodium succinate/PF), 1,000 mg/8 mL, Vial, 1 |
01/01/2022 |
22.83 |
136.98 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00009001103 |
SOLU-CORTEF (hydrocortisone sodium succinate/PF), 100 mg / 2 mL, Vial, 1 |
01/01/2022 |
3.08 |
18.50 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00009001104 |
SOLU-CORTEF (hydrocortisone sodium succinate/PF), 100 mg/2 mL, Vial, 1 |
01/01/2022 |
77.13 |
462.76 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00009001305 |
SOLU-CORTEF (hydrocortisone sodium succinate/PF), 250 mg / 2 mL, Vial, 1 |
01/01/2022 |
5.71 |
34.24 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00009001306 |
SOLU-CORTEF (hydrocortisone sodium succinate/PF), 250 mg/2 mL, Vial, 1 |
01/01/2022 |
142.66 |
855.96 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00009001612 |
SOLU-CORTEF (hydrocortisone sodium succinate/PF), 500 mg/4 mL, Vial, 1 |
01/01/2022 |
11.42 |
68.50 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00069055038 |
SUTENT (sunitinib malate), 12.5 mg, CAPSULE, 1 |
01/01/2022 |
311.23 |
5969.88 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00069077038 |
SUTENT (sunitinib malate), 25 mg, CAPSULE, 1 |
01/01/2022 |
622.45 |
11939.77 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00069083038 |
SUTENT (sunitinib malate), 37.5 mg, CAPSULE, 1 |
01/01/2022 |
933.68 |
17909.66 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00069098038 |
SUTENT (sunitinib malate), 50 mg, CAPSULE, 1 |
01/01/2022 |
1083.60 |
20785.45 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00005010010 |
TRUMENBA (Neisseria meningitidis group B, lipidated fHBP recombinant), 120 mcg / 0.5 mL, SYRINGE (ML), 1 |
01/01/2022 |
108.05 |
1674.04 |
10/01/2026 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
(4) The patent expiration date listed is based on regulatory exclusivity. |
Rx0000006 |
Pfizer |
03/31/2022 |
00005010005 |
TRUMENBA (Neisseria meningitidis group B, lipidated fHBP recombinant), 120 mcg/0.5 mL, SYRINGE (ML), 1 |
01/01/2022 |
54.02 |
837.02 |
10/01/2026 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
(4) The patent expiration date listed is based on regulatory exclusivity. |
Rx0000006 |
Pfizer |
09/30/2022 |
00409963305 |
Verapamil Hydrochloride Injection Rx, 2.5 mg/mL (10 mg/4 mL) Ansyr™ Plastic Syringe, 10 |
07/01/2022 |
55.50 |
610.48 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00069019730 |
VIZIMPRO (dacomitinib), 15 mg, TABLET, 1 |
01/01/2022 |
751.91 |
14422.91 |
08/01/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
(4) The patent expiration date listed is based on a pending patent term extension application and the patent expiry date is expected to be 2028 upon the grant of the patent term extension application. |
Rx0000006 |
Pfizer |
03/31/2022 |
00069119830 |
VIZIMPRO (dacomitinib), 30 mg, TABLET, 1 |
01/01/2022 |
751.91 |
14422.91 |
08/01/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
(4) The patent expiration date listed is based on a pending patent term extension application and the patent expiry date is expected to be 2028 upon the grant of the patent term extension application. |
Rx0000006 |
Pfizer |
03/31/2022 |
00069229930 |
VIZIMPRO (dacomitinib), 45 mg, TABLET, 1 |
01/01/2022 |
751.91 |
14422.91 |
08/01/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
(4) The patent expiration date listed is based on a pending patent term extension application and the patent expiry date is expected to be 2028 upon the grant of the patent term extension application. |
Rx0000006 |
Pfizer |
03/31/2022 |
00069814120 |
XALKORI (crizotinib), 200 mg, CAPSULE, 1 |
01/01/2022 |
1022.26 |
19608.87 |
10/08/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00069814020 |
XALKORI (crizotinib), 250 mg, CAPSULE, 1 |
01/01/2022 |
1022.26 |
19608.87 |
10/08/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00069100201 |
XELJANZ (tofacitinib citrate), 10 mg, TABLET, 1 |
01/01/2022 |
271.18 |
5201.67 |
12/08/2025 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00069100101 |
XELJANZ (tofacitinib citrate), 5 mg, TABLET, 1 |
01/01/2022 |
271.18 |
5201.67 |
12/08/2025 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000006 |
Pfizer |
03/31/2022 |
00069050130 |
XELJANZ XR (tofacitinib citrate), 11 mg, TABLET, EXTENDED RELEASE 24 HR, 1 |
01/01/2022 |
271.18 |
5201.67 |
12/08/2025 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
Rx0000135 |
Pharmaceutical Associates, Inc |
03/31/2022 |
00121050400 |
Acetaminophen & Codeine Phosphate CV 120mg/12mg, 5mL 100/cs |
03/15/2022 |
111.30 |
234.97 |
None |
Non-innovator Multiple Source Drug |
0 |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000135 |
Pharmaceutical Associates, Inc |
03/31/2022 |
00121100800 |
Acetaminophen & Codeine Phosphate CV 300mg/30mg, 12.5mL 100/cs |
03/15/2022 |
131.22 |
277.02 |
None |
Non-innovator Multiple Source Drug |
0 |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000135 |
Pharmaceutical Associates, Inc |
03/31/2022 |
00121064610 |
AMANTADINE HCL50 mg/5 mL, 10 TRAY in 1 CASE (0121-0646-10) > 10 CUP, UNIT-DOSE in 1 TRAY > 10 mL in 1 CUP, UNIT-DOSE |
03/15/2022 |
106.95 |
320.85 |
None |
Non-innovator Multiple Source Drug |
0 |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000135 |
Pharmaceutical Associates, Inc |
03/31/2022 |
00121097800 |
Diphenhydramine HCL 12.5mg/5mL (10mL), 10 TRAY in 1 CASE (0121-0978-00) > 10 CUP, UNIT-DOSE in 1 TRAY > 10 mL in 1 CUP, UNIT-DOSE (0121-0978-10) |
03/15/2022 |
62.66 |
375.95 |
None |
Non-innovator Multiple Source Drug |
0 |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000135 |
Pharmaceutical Associates, Inc |
03/31/2022 |
00121048900 |
Diphenhydramine HCL 12.5mg/5mL, 10 TRAY in 1 CASE (0121-0489-00) > 10 CUP, UNIT-DOSE in 1 TRAY > 5 mL in 1 CUP, UNIT-DOSE (0121-0489-05) |
03/15/2022 |
80.60 |
379.13 |
None |
Non-innovator Multiple Source Drug |
0 |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000135 |
Pharmaceutical Associates, Inc |
03/31/2022 |
00121065416 |
FLUPHENAZINE HCL2.5 mg/5 mL, 473 mL in 1 BOTTLE (0121-0654-16) |
03/15/2022 |
66.36 |
255.96 |
None |
Non-innovator Multiple Source Drug |
0 |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000135 |
Pharmaceutical Associates, Inc |
03/31/2022 |
00121157610 |
METOCLOPRAMIDE HCL10 mg/10 mL, 10 TRAY in 1 CASE (0121-1576-10) > 10 CUP, UNIT-DOSE in 1 TRAY > 10 mL in 1 CUP, UNIT-DOSE |
03/15/2022 |
166.91 |
352.36 |
None |
Non-innovator Multiple Source Drug |
0 |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000135 |
Pharmaceutical Associates, Inc |
03/31/2022 |
00121119000 |
Sodium Citrate/ Citric Acid 30 mL, 10 TRAY in 1 CASE (0121-1190-00) > 10 CUP, UNIT-DOSE in 1 TRAY > 30 mL in 1 CUP, UNIT-DOSE (0121-1190-30) |
03/15/2022 |
106.51 |
461.55 |
None |
Non-innovator Multiple Source Drug |
0 |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000135 |
Pharmaceutical Associates, Inc |
03/31/2022 |
00121059500 |
Sodium Citrate/ Citric Acid, 10 TRAY in 1 CASE (0121-0595-00) > 10 CUP, UNIT-DOSE in 1 TRAY > 15 mL in 1 CUP, UNIT-DOSE (0121-0595-15) |
03/15/2022 |
98.15 |
425.33 |
None |
Non-innovator Multiple Source Drug |
0 |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000135 |
Pharmaceutical Associates, Inc |
03/31/2022 |
00121085340 |
Sulfamethoxazole and Trimethoprim Oral Solution USP, 4 TRAY in 1 CASE (0121-0853-40) > 10 CUP, UNIT-DOSE in 1 TRAY > 20 mL in 1 CUP, UNIT-DOSE (0121-0853-20) |
03/15/2022 |
91.77 |
397.68 |
None |
Non-innovator Multiple Source Drug |
0 |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000135 |
Pharmaceutical Associates, Inc |
03/31/2022 |
00121135000 |
Valproic Acid Oral Solution, 10 TRAY in 1 CASE (0121-1350-00) > 10 CUP, UNIT-DOSE in 1 TRAY > 10 mL in 1 CUP, UNIT-DOSE (0121-1350-10) |
03/15/2022 |
75.95 |
160.34 |
None |
Non-innovator Multiple Source Drug |
0 |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000135 |
Pharmaceutical Associates, Inc |
03/31/2022 |
00121467500 |
Valproic Acid Oral Solution, 10 TRAY in 1 CASE (0121-4675-00) > 10 CUP, UNIT-DOSE in 1 TRAY > 5 mL in 1 CUP, UNIT-DOSE (0121-4675-05) |
03/15/2022 |
41.63 |
87.88 |
None |
Non-innovator Multiple Source Drug |
0 |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000135 |
Pharmaceutical Associates, Inc |
03/31/2022 |
00121467540 |
Valproic Acid Oral Solution, 4 TRAY in 1 CASE (0121-4675-40) > 10 CUP, UNIT-DOSE in 1 TRAY > 5 mL in 1 CUP, UNIT-DOSE (0121-4675-05) |
03/15/2022 |
26.61 |
56.18 |
None |
Non-innovator Multiple Source Drug |
0 |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000237 |
Pharmacyclics an AbbVie Company |
03/31/2022 |
57962014012 |
Imbruvica 120 Oral Capsule 140 MG |
01/14/2022 |
1472.13 |
21365.82 |
10/24/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000237 |
Pharmacyclics an AbbVie Company |
03/31/2022 |
57962007028 |
Imbruvica 28 Oral Capsule 70 MG |
01/14/2022 |
1030.49 |
14956.08 |
10/24/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000237 |
Pharmacyclics an AbbVie Company |
03/31/2022 |
57962001428 |
Imbruvica 28 Oral Tablet 140 MG |
01/14/2022 |
1030.49 |
14956.08 |
03/03/2036 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000237 |
Pharmacyclics an AbbVie Company |
03/31/2022 |
57962028028 |
Imbruvica 28 Oral Tablet 280 MG |
01/14/2022 |
1030.49 |
14956.08 |
03/03/2036 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000237 |
Pharmacyclics an AbbVie Company |
03/31/2022 |
57962042028 |
Imbruvica 28 Oral Tablet 420 MG |
01/14/2022 |
1030.49 |
14956.08 |
03/03/2036 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000237 |
Pharmacyclics an AbbVie Company |
03/31/2022 |
57962056028 |
Imbruvica 28 Oral Tablet 560 MG |
01/14/2022 |
1030.49 |
14956.08 |
03/03/2036 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000237 |
Pharmacyclics an AbbVie Company |
03/31/2022 |
57962014009 |
Imbruvica 90 Oral Capsule 140 MG |
01/14/2022 |
1104.10 |
16024.37 |
10/24/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000289 |
Piramal Critical Care |
09/30/2022 |
66794001725 |
Isoflurane Inhallation Solution 250 ml 1 bottle |
07/01/2022 |
10.00 |
40.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000289 |
Piramal Critical Care |
09/30/2022 |
66794001925 |
Terrell Isoflurane Inhallation Solution 250 ml 1 bottle |
07/01/2022 |
10.00 |
40.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000347 |
Primus Pharmaceuticals Inc |
12/31/2022 |
68040071338 |
IMPOYZ® External Cream; Clobetasol propionate 0.025%; Cream; 100g |
11/21/2022 |
115.00 |
1350.00 |
08/31/2030 |
Single Source Drug |
None |
1 |
None |
1 |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000347 |
Primus Pharmaceuticals Inc |
12/31/2022 |
68040071428 |
Sernivo® Spray; Betamethasone dipropionate 0.05%; Emulsion Spray; 120g in 1 bottle |
11/21/2022 |
92.50 |
1090.00 |
08/31/2030 |
Single Source Drug |
None |
1 |
None |
1 |
N/A |
None |
03/01/2021 |
Encore Dermatology |
None |
1 |
None |
997.50 |
902.95 |
2017 |
859.95 |
None |
None |
Rx0000236 |
PTC Therapeutics, Inc |
03/31/2022 |
52856050203 |
EMFLAZA (deflazacort) 18mg tabs/ 30 ct |
01/17/2022 |
528.44 |
6465.94 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/01/2017 |
Marathon Pharmaceuticals |
140000000 |
None |
None |
3925.00 |
0.00 |
2017 |
3925.00 |
None |
Price increase for all strengths only includes PTC NCD related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market. |
Rx0000236 |
PTC Therapeutics, Inc |
09/30/2022 |
52856050203 |
EMFLAZA (deflazacort) 18mg tabs/30 ct |
07/18/2022 |
607.79 |
7073.73 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/01/2017 |
Marathon Pharmaceuticals |
140000000 |
None |
None |
3925.00 |
0.00 |
2017 |
3925.00 |
None |
Price increase for all strengths only includes PTC NDC related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market. |
Rx0000236 |
PTC Therapeutics, Inc |
03/31/2022 |
52856050522 |
EMFLAZA (deflazacort) 22.75 mg/ml susp/13 mL in 1 BOTTLE |
01/17/2022 |
386.80 |
4732.90 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/01/2017 |
Marathon Pharmaceuticals |
140000000 |
None |
None |
2873.00 |
0.00 |
2017 |
2873.00 |
None |
Price increase for all strengths only includes PTC NCD related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market. |
Rx0000236 |
PTC Therapeutics, Inc |
09/30/2022 |
52856050522 |
EMFLAZA (deflazacort) 22.75 mg/ml susp/13 mL in 1 BOTTLE |
07/18/2022 |
444.89 |
5177.79 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/01/2017 |
Marathon Pharmaceuticals |
140000000 |
None |
None |
2873.00 |
0.00 |
2017 |
2873.00 |
None |
Price increase for all strengths only includes PTC NDC related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market. |
Rx0000236 |
PTC Therapeutics, Inc |
03/31/2022 |
52856050303 |
EMFLAZA (deflazacort) 30mg tabs/ 30 ct |
01/17/2022 |
880.78 |
10777.11 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/01/2017 |
Marathon Pharmaceuticals |
140000000 |
None |
None |
6542.00 |
0.00 |
2017 |
6542.00 |
None |
Price increase for all strengths only includes PTC NCD related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market. |
Rx0000236 |
PTC Therapeutics, Inc |
09/30/2022 |
52856050303 |
EMFLAZA (deflazacort) 30mg tabs/30 ct |
07/18/2022 |
1013.05 |
11790.16 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/01/2017 |
Marathon Pharmaceuticals |
140000000 |
None |
None |
6542.00 |
0.00 |
2017 |
6542.00 |
None |
Price increase for all strengths only includes PTC NDC related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market. |
Rx0000236 |
PTC Therapeutics, Inc |
03/31/2022 |
52856050403 |
EMFLAZA (deflazacort) 36mg tabs/ 30 ct |
01/17/2022 |
1019.60 |
12475.73 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/01/2017 |
Marathon Pharmaceuticals |
140000000 |
None |
None |
7290.00 |
0.00 |
2017 |
7290.00 |
None |
Price increase for all strengths only includes PTC NCD related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market. |
Rx0000236 |
PTC Therapeutics, Inc |
09/30/2022 |
52856050403 |
EMFLAZA (deflazacort) 36mg tabs/30 ct |
07/18/2022 |
1172.72 |
13648.45 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/01/2017 |
Marathon Pharmaceuticals |
140000000 |
None |
None |
7290.00 |
0.00 |
2017 |
7290.00 |
None |
Price increase for all strengths only includes PTC NDC related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market. |
Rx0000236 |
PTC Therapeutics, Inc |
03/31/2022 |
52856050101 |
EMFLAZA (deflazacort) 6mg tabs/100 ct |
01/17/2022 |
587.13 |
7184.19 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/01/2017 |
Marathon Pharmaceuticals |
140000000 |
None |
None |
4361.00 |
0.00 |
2017 |
4361.00 |
None |
Price increase for all strengths only includes PTC NCD related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market. |
Rx0000236 |
PTC Therapeutics, Inc |
09/30/2022 |
52856050101 |
EMFLAZA (deflazacort) 6mg tabs/100 ct |
07/18/2022 |
675.31 |
7859.50 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/01/2017 |
Marathon Pharmaceuticals |
140000000 |
None |
None |
4361.00 |
0.00 |
2017 |
4361.00 |
None |
Price increase for all strengths only includes PTC NDC related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market. |
Rx0000220 |
Puma Biotechnology, Inc. |
03/31/2022 |
70437024018 |
Nerlynx Oral Tablet 40 mg, 180 tablet package |
01/10/2022 |
900.00 |
19275.00 |
07/18/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000342 |
PureTek Corporation |
06/30/2022 |
59088017854 |
Pretrate, prenatal/ postnatal multivitamin, caplets, 30ct, Vitamin A 1500mcg, Vitamin C 120mg, Vitamin D3 20mcg, Vitamin E 30mg, Thiamin 3mg, Riboflavin 3.4mg, Niacin 20mg, Vitamin B6 50mg, Folate 1700mcg DFE, Vitamin B12 10mcg, Choline 55mg, Calcium 200mg, Iron 27mg, Iodine 150mcg, Magnesium 200mg, Zinc 25mg, Selenium 70mcg, Manganese 2.6mg, Chromium 45mcg, Molybdenum 50mcg |
06/30/2022 |
220.00 |
1680.00 |
None |
Single Source Drug |
807 |
None |
Raw material and labor |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |